RecruitingPhase 4NCT06154083

INtensity of OVarian Stimualtion and Euploid Embryos

The Impact of Ovarian Stimulation Intensity on Embryo Euploidy in Advanced Age Women


Sponsor

Fundación Santiago Dexeus Font

Enrollment

110 participants

Start Date

Dec 12, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with a PPOS protocol.


Eligibility

Sex: FEMALEMin Age: 38 YearsMax Age: 42 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Follitropin-delta (Rekovelle) 15 mcg/day from D1 and a drug called Follitropin-delta (Rekovelle) 20 mcg/day from D1 for people with fertility. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 38 Years to 42 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFollitropin-delta (Rekovelle) 20 mcg/day from D1

On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.

DRUGFollitropin-delta (Rekovelle) 15 mcg/day from D1

On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.


Locations(1)

Hospital Universitario Quiron Dexeus

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06154083


Related Trials